



10-18-01
1014 Rec'd PCT/PTO

12 DEC 2001

PCT
#3

Practitioner's Docket No. MWH-0031US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Liggett, Stephen B.

Application No.: 09/936,499

Group No.: To Be Determined

Filed: September 12, 2001

Examiner: To Be Determined

For: Variation in Drug Response Related to Polymorphisms in Beta-2 Adrenergic Receptor

Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS OF FILING OR
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. section 1.97(b))

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

CERTIFICATION UNDER 37 C.F.R. SECTION 1.10*


(Express Mail label number is **mandatory**)

(Express Mail certification is **optional**)

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service on Dec. 12, 2001 (date), in an envelope as "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. Section 1.10, Mailing Label Number 1014 US addressed to Box PCT, Assistant Commissioner for Patents, Washington, D.C. 20231.

Cathy Wilcox

(type or print name of person mailing paper)



Cathy Wilcox
Signature of person mailing

(Transmittal of Information Disclosure Statement Within Three Months of Filing or Before Mailing of First Office Action--page 1 of 2)

Date: 12/12/01

Reg. No.: 47,562
Tel. No.: 203-786-3473
Customer No.: 25106

Gisela M. Field

Signature of Practitioner

Gisela M. Field
Genaissance Pharmaceuticals, Inc.
5 Science Park
New Haven, CT 06511



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A (REO)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

She

1

Complete if Known

| | |
|------------------------|--------------------|
| Application Number | 09/936,499 |
| Filing Date | 09/12/2001 |
| First Named Inventor | Stephen B. Liggett |
| Art Unit | |
| Examiner Name | |
| Attorney Docket Number | MWH-0031US |

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature _____ Date Considered _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance.

Applicant's unique citation number (code) (See *Text Communications* to applicant).
Applicant must indicate the date that issued the patent by the two codes WIPO Standard ST.3. ⁴ For Japanese patent documents, the date of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the two codes WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if

English language translation is attached.
Billed Hour Statement: The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the form or the use of this form are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Substitute for form 1449B/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

| | |
|------------------------|--------------------|
| Application Number | 09/936,499 |
| Filing Date | 09/12/2001 |
| First Named Inventor | Stephen B. Liggett |
| Group Art Unit | |
| Examiner Name | |
| Attorney Docket Number | MWH-0031US |

OTHER PRIOR ART-- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No.! | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and country where published. | T# |
|--------------------|-----------|--|----|
| • | BA | GREEN, S.B. ET AL., "Influence of B2-Adrenergic Receptor Genotypes on Signal Transduction in Human Airway Smooth Muscle Cells," Am. J. Respir. Cell Mol. Biol., Vol. 13, p. 25-33, (1995). | |
| • | BB | GREEN, S.B. ET AL., "Amino-Terminal Polymorphisms of the Human B2-Adrenergic Receptor Impart Distinct Agonist-Promoted Regulatory Properties," Biochemistry, Vol. 33, p. 9414-9419, (1994). | |
| • | BC | GREEN, S.B. ET AL., "A Polymorphism of the Human B2-Adrenergic Receptor within the Fourth Transmembrane Domain Alters Ligand Binding and Functional Properties of the Receptor," The Journal of Biological Chemistry, Vol. 268, p.23116-21, (1993). | |
| • | BD | HALL, IAN ET AL., "Association of Glu27 B2-Adrenoceptor Polymorphism with Lower Airway Reactivity in Asthmatic Subjects," The Lancet, Vol. 345, p. 1213-4, (1995). | |
| • | BE | LIGGETT, S.B., "Functional Properties of Human B2-Adrenergic Receptor Polymorphisms," News in Physiological Sciences, Vol. 10, p. 265-273, (1995). | |
| • | BF | LIGGETT, S.B., "The Genetics of B2-Adrenergic Receptor Polymorphisms: Relevance to Receptor Function and Asthmatic Phenotypes," The Genetics of Asthma, 1st ed., Marcel Dekker (New York), p. 455-478, (1996). | |
| • | BG | LIGGETT, S.B. ET AL., "The Ile164 B2-Adrenergic Receptor Polymorphism Adversely Affects the Outcome of Congestive Heart Failure," J. Clin. Invest., Vol. 102 (No. 8), p. 1534-1539, (1998). | |
| • | BH | LIGGETT, S.B., "Polymorphisms in the 5' Leader Cistron of the B2-Adrenergic Receptor," Pending U.S. Application, Serial No.09/856,803, (Filed May 25, 2001). | |
| • | BI | MCGRAW, D.W. ET AL., "Polymorphisms in the 5' Leader Cistron of the Human B2-Adrenergic Receptor Regulate Receptor Expression," J. Clin. Invest., Vol. 102 (No. 11), p. 1927-1932, (1998). | |
| • | BJ | REIHSaus, ELLEN ET AL., "Mutations in the Gene Encoding for the B2-Adrenergic Receptor In Normal and Asthmatic Subjects," Am. J. Respir. Cell Mol. Biol., Vol. 8, p. 334-339, (1993). | |
| • | BK | TURKI, JAMAL ET AL., "Genetic Polymorphism of the B2-Adrenergic Receptor in Nocturnal and Nonnocturnal Asthma," J. Clin. Invest., p. 1635-1641, (1995). | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comment on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.